Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Orchestra BioMed Holdings (OBIO) Other Non-Current Liabilities (2022 - 2025)

Orchestra BioMed Holdings (OBIO) has disclosed Other Non-Current Liabilities for 4 consecutive years, with $248000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Other Non-Current Liabilities changed N/A to $248000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $248000.0, a N/A change, with the full-year FY2024 number at $40000.0, changed N/A from a year prior.
  • Other Non-Current Liabilities was $248000.0 for Q3 2025 at Orchestra BioMed Holdings, up from $189000.0 in the prior quarter.
  • In the past five years, Other Non-Current Liabilities ranged from a high of $2.4 million in Q1 2023 to a low of $40000.0 in Q4 2024.
  • A 4-year average of $682333.3 and a median of $248000.0 in 2025 define the central range for Other Non-Current Liabilities.
  • Biggest YoY gain for Other Non-Current Liabilities was 280.29% in 2023; the steepest drop was 280.29% in 2023.
  • Orchestra BioMed Holdings' Other Non-Current Liabilities stood at $2.1 million in 2022, then plummeted by 87.27% to $266000.0 in 2023, then tumbled by 84.96% to $40000.0 in 2024, then skyrocketed by 520.0% to $248000.0 in 2025.
  • Per Business Quant, the three most recent readings for OBIO's Other Non-Current Liabilities are $248000.0 (Q3 2025), $189000.0 (Q2 2025), and $99000.0 (Q1 2025).